

**Rituximab (MabThera<sup>®</sup>)**

**(No. 33/03)**

**Roche**

Summary of Recommendation

7 February, 2003

The Scottish Medicines Consortium (SMC) has completed its assessment of the above product and advises NHS Boards and ADTCs on its use in NHS Scotland. The recommendation is summarised as follows:

**ADVICE**

Recommended for restricted use within NHS Scotland for the treatment of patients with CD20 positive diffuse large B-cell non-Hodgkin's lymphoma.

**REASONS FOR ADVICE**

Rituximab is recommended for use by oncologists or haematologists in Scotland who have expertise in treating lymphoma. It should be administered in a hospital environment where full resuscitation facilities are available.

Professor David H Lawson  
Chairman